BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 20940694)

  • 1. Tissue-based molecular markers for bladder cancer.
    Barbieri CE; Lotan Y; Lee RK; Sonpavde G; Karakiewicz PI; Robinson B; Scherr DS; Shariat SF
    Minerva Urol Nefrol; 2010 Sep; 62(3):241-58. PubMed ID: 20940694
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Predictive value of cell cycle biomarkers in nonmuscle invasive bladder transitional cell carcinoma.
    Shariat SF; Ashfaq R; Sagalowsky AI; Lotan Y
    J Urol; 2007 Feb; 177(2):481-7; discussion 487. PubMed ID: 17222615
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunohistochemical biomarkers for bladder cancer prognosis.
    Matsushita K; Cha EK; Matsumoto K; Baba S; Chromecki TF; Fajkovic H; Sun M; Karakiewicz PI; Scherr DS; Shariat SF
    Int J Urol; 2011 Sep; 18(9):616-29. PubMed ID: 21771101
    [TBL] [Abstract][Full Text] [Related]  

  • 4. WAF1/p21 protein expression is an independent prognostic indicator in superficial and invasive bladder cancer.
    Korkolopoulou P; Konstantinidou AE; Thomas-Tsagli E; Christodoulou P; Kapralos P; Davaris P
    Appl Immunohistochem Mol Morphol; 2000 Dec; 8(4):285-92. PubMed ID: 11127920
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Minichromosome maintenance proteins 2 and 5 expression in muscle-invasive urothelial cancer: a multivariate survival study including proliferation markers and cell cycle regulators.
    Korkolopoulou P; Givalos N; Saetta A; Goudopoulou A; Gakiopoulou H; Thymara I; Thomas-Tsagli E; Patsouris E
    Hum Pathol; 2005 Aug; 36(8):899-907. PubMed ID: 16112007
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predictive value of cell cycle markers p53, MDM2, p21, and Ki-67 in superficial bladder tumor recurrence.
    Pfister C; Moore L; Allard P; Larue H; Lacombe L; Têtu B; Meyer F; Fradet Y
    Clin Cancer Res; 1999 Dec; 5(12):4079-84. PubMed ID: 10632343
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association of cyclin D1 and E1 expression with disease progression and biomarkers in patients with nonmuscle-invasive urothelial cell carcinoma of the bladder.
    Shariat SF; Ashfaq R; Sagalowsky AI; Lotan Y
    Urol Oncol; 2007; 25(6):468-75. PubMed ID: 18047954
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular and immunohistochemical analysis of the prognostic value of cell-cycle regulators in urothelial neoplasms of the bladder.
    Yurakh AO; Ramos D; Calabuig-Fariñas S; López-Guerrero JA; Rubio J; Solsona E; Romanenko AM; Vozianov AF; Pellin A; Llombart-Bosch A
    Eur Urol; 2006 Sep; 50(3):506-15; discussion 515. PubMed ID: 16624482
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combination of multiple molecular markers can improve prognostication in patients with locally advanced and lymph node positive bladder cancer.
    Shariat SF; Chade DC; Karakiewicz PI; Ashfaq R; Isbarn H; Fradet Y; Bastian PJ; Nielsen ME; Capitanio U; Jeldres C; Montorsi F; Lerner SP; Sagalowsky AI; Cote RJ; Lotan Y
    J Urol; 2010 Jan; 183(1):68-75. PubMed ID: 19913255
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expression of cell cycle proteins in T1a and T1b urothelial bladder carcinoma and their value in predicting tumor progression.
    Mhawech P; Greloz V; Oppikofer C; Szalay-Quinodoz I; Herrmann F
    Cancer; 2004 Jun; 100(11):2367-75. PubMed ID: 15160340
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic value of molecular markers, sub-stage and European Organisation for the Research and Treatment of Cancer risk scores in primary T1 bladder cancer.
    van Rhijn BW; Liu L; Vis AN; Bostrom PJ; Zuiverloon TC; Fleshner NE; van der Aa MN; Alkhateeb SS; Bangma CH; Jewett MA; Zwarthoff EC; Bapat B; van der Kwast TH; Zlotta AR
    BJU Int; 2012 Oct; 110(8):1169-76. PubMed ID: 22448597
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Urothelial carcinoma of the bladder and the upper tract: disparate twins.
    Green DA; Rink M; Xylinas E; Matin SF; Stenzl A; Roupret M; Karakiewicz PI; Scherr DS; Shariat SF
    J Urol; 2013 Apr; 189(4):1214-21. PubMed ID: 23023150
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular alterations associated with bladder cancer initiation and progression.
    Cordon-Cardo C
    Scand J Urol Nephrol Suppl; 2008 Sep; (218):154-65. PubMed ID: 18815930
    [TBL] [Abstract][Full Text] [Related]  

  • 14. p53, p21, pRB, and p16 expression predict clinical outcome in cystectomy with bladder cancer.
    Shariat SF; Tokunaga H; Zhou J; Kim J; Ayala GE; Benedict WF; Lerner SP
    J Clin Oncol; 2004 Mar; 22(6):1014-24. PubMed ID: 14981102
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Predictive value of combined immunohistochemical markers in patients with pT1 urothelial carcinoma at radical cystectomy.
    Shariat SF; Bolenz C; Godoy G; Fradet Y; Ashfaq R; Karakiewicz PI; Isbarn H; Jeldres C; Rigaud J; Sagalowsky AI; Lotan Y
    J Urol; 2009 Jul; 182(1):78-84; discussion 84. PubMed ID: 19447418
    [TBL] [Abstract][Full Text] [Related]  

  • 16. p53 and p21 Expression levels predict organ preservation and survival in invasive bladder carcinoma treated with a combined-modality approach.
    Garcia del Muro X; Condom E; Vigués F; Castellsagué X; Figueras A; Muñoz J; Solá J; Soler T; Capellà G; Germà JR
    Cancer; 2004 May; 100(9):1859-67. PubMed ID: 15112266
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expression of topoisomerase II alpha, ki67, and p53 in primary non-muscle-invasive urothelial bladder carcinoma.
    Ben Abdelkrim S; Rammeh S; Ziadi S; Tlili T; Jaidane M; Mokni M
    J Immunoassay Immunochem; 2014; 35(4):358-67. PubMed ID: 24624938
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic significance of p53, bcl-2 and Ki-67 in high risk superficial bladder cancer.
    Stavropoulos NE; Filiadis I; Ioachim E; Hastazeris K; Tsimaris I; Kalogeras D; Stefanaki S; Agnantis NJ
    Anticancer Res; 2002; 22(6B):3759-64. PubMed ID: 12552989
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Correlation and prognostic significance of p53, p21WAF1/CIP1 and Ki-67 expression in patients with superficial bladder tumors treated with bacillus Calmette-Guerin intravesical therapy.
    Zlotta AR; Noel JC; Fayt I; Drowart A; Van Vooren JP; Huygen K; Simon J; Schulman CC
    J Urol; 1999 Mar; 161(3):792-8. PubMed ID: 10022686
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association of angiogenesis related markers with bladder cancer outcomes and other molecular markers.
    Shariat SF; Youssef RF; Gupta A; Chade DC; Karakiewicz PI; Isbarn H; Jeldres C; Sagalowsky AI; Ashfaq R; Lotan Y
    J Urol; 2010 May; 183(5):1744-50. PubMed ID: 20299037
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.